The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort
The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort
复制标题
DOI:
10.1186/s13054-019-2665-5
复制
发表时间:
2019-11-29
期刊:
影响因子:
15.1
通讯作者:
Giamarellos-Bourboulis, Evangelos J.
中科院分区:
文献类型:
--
作者:
Karakike, Eleni;Kyriazopoulou, Evdoxia;Giamarellos-Bourboulis, Evangelos J.
Background Since the Sepsis-3 criteria, change in Sequential Organ Failure Assessment (SOFA) score has become a key component of sepsis identification. Thus, it could be argued that reversal of this change (Delta(SOFA)) may reflect sepsis response and could be used as measure of efficacy in interventional trials. We aimed to assess the predictive performance of Delta(SOFA) for 28-day mortality. Methods Data from two previously published randomized controlled trials were studied: the first reporting on patients with severe Gram-negative infections as a derivation cohort and the second reporting on patients with ventilator-associated pneumonia as a validation cohort. Only patients with sepsis according to the Sepsis-3 definition were included in this analysis. SOFA scores were calculated on days 1, 2, 3, 5, 7, 14, and 28. Results We included 448 patients within the derivation cohort and 199 within the validation cohort. Mean SOFA scores on day 1 were 6.06 +/- 4.07 and 7.84 +/- 3.39, and 28 day mortality 22.8% and 29.6%, respectively. In the derivation cohort, the earliest time point where Delta(SOFA) score predicted mortality was day 7 (AUROC (95% CI) 0.84 (0.80-0.89); p < 0.001). The best tradeoff for prediction was found with 25% changes (78% sensitivity, 80% specificity); less than 25% decrease of admission SOFA was associated with increased mortality (odds ratio for death 14.87). This finding was confirmed in the validation cohort. Conclusions Delta(SOFA) on day 7 is a useful early prognostic marker of 28-day mortality and could serve as an endpoint in future sepsis trials alongside mortality.